{"id":443,"date":"2025-10-06T08:25:30","date_gmt":"2025-10-06T15:25:30","guid":{"rendered":"https:\/\/getasecondopinion.ai\/blog\/?p=443"},"modified":"2025-10-06T08:25:31","modified_gmt":"2025-10-06T15:25:31","slug":"the-anda-prioritization-pilot-is-a-smart-strategic-move-to-rebuild-u-s-generic-drug-manufacturing-capacity","status":"publish","type":"post","link":"https:\/\/www.getasecondopinion.ai\/blog\/news\/the-anda-prioritization-pilot-is-a-smart-strategic-move-to-rebuild-u-s-generic-drug-manufacturing-capacity\/","title":{"rendered":"The ANDA Prioritization Pilot Is a Smart, Strategic Move to Rebuild U.S. Generic Drug Manufacturing Capacity"},"content":{"rendered":"\n<p>The Food and Drug Administration\u2019s new ANDA Prioritization Pilot realigns regulatory incentives to reward onshore bioequivalence testing and U.S. manufacturing of finished dosage forms and active pharmaceutical ingredients (API), and it will strengthen supply\u2011chain resilience, lower inspection costs, and speed patient access to affordable generics. The policy leverages FDA review speed as a targeted market signal: companies that invest in U.S. testing and production can secure priority review for their abbreviated new drug applications (ANDAs), giving domestic manufacturers a predictable regulatory advantage.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">Why this matters&nbsp;<\/h3>\n\n\n\n<p>More than half of pharmaceuticals distributed in the U.S. rely on overseas manufacturing and testing, creating vulnerability to disruptions, slower inspections, and higher taxpayer inspection costs. By making priority review contingent on pivotal bioequivalence studies conducted in the U.S. and on domestic API and finished-dose manufacturing, the pilot creates a clear, enforceable pathway for reshoring high\u2011value activities and rebuilding onshore technical capacity.<\/p>\n\n\n\n<p><strong>Policy design strengths<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Rewards U.S. bioequivalence testing, U.S. finished\u2011dose manufacturing, and U.S. API supply with a valuable regulatory benefit &#8211; faster ANDA review.<\/li>\n\n\n\n<li>Low administrative burden for applicants &#8211; priority requests follow FDA\u2019s existing MAPP 5240.3 procedures and require straightforward documentation of testing and manufacturing locations.<\/li>\n\n\n\n<li>Aligned with broader FDA initiatives such as PreCheck to accelerate establishment of priority manufacturing facilities in the U.S., creating complementary pathways for investment and facility readiness.<\/li>\n<\/ul>\n\n\n\n<p><strong>Risks and implementation challenges<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Supply\u2011chain economics may limit near\u2011term uptake. Building U.S. API capacity and testing infrastructure requires capital, skilled personnel, and multi\u2011year timelines. Firms may need additional incentives beyond review speed to onshore critical steps.<\/li>\n\n\n\n<li>Verification and inspection workload could shift rather than shrink. Increased domestic facilities mean more U.S. inspections and oversight resources will be required even as foreign inspection demands decline.<\/li>\n\n\n\n<li>Equity of priority selection. The FDA must maintain transparency in prioritization adjudication to avoid unintended market distortions or favoritism while preserving public\u2011health priorities.<\/li>\n<\/ul>\n\n\n\n<p><strong>Recommendations to maximize impact<\/strong><\/p>\n\n\n\n<ol class=\"wp-block-list\">\n<li>Pair the ANDA Prioritization Pilot with targeted financial incentives such as tax credits, low\u2011interest loans, or matching grants for U.S. API and bioequivalence lab expansion to accelerate private investment.<\/li>\n\n\n\n<li>Publish clear metrics and a timetable for measuring pilot outcomes. Number of ANDAs granted priority, shift in domestic API share, inspection workload changes, etc &#8211; to enable data\u2011driven adjustments.<\/li>\n\n\n\n<li>Expand workforce development support for analytical, bioequivalence, and manufacturing technicians to ensure capacity growth is sustainable.<\/li>\n\n\n\n<li>Coordinate with reimbursement and procurement levers (public purchasers, Medicaid formularies) to create demand signals for U.S\u2011made generics when clinically appropriate.<\/li>\n<\/ol>\n\n\n\n<div class=\"wp-block-group unauthenticated invisible has-border-color has-accent-2-border-color has-base-color has-text-color has-background has-link-color wp-elements-39b963853d7817e16094319813ac27da has-global-padding is-layout-constrained wp-container-core-group-is-layout-68a6995b wp-block-group-is-layout-constrained\" style=\"border-width:15px;border-radius:30px;background-color:#f7faf9;margin-top:var(--wp--preset--spacing--40);margin-bottom:var(--wp--preset--spacing--40);padding-top:var(--wp--preset--spacing--40);padding-right:var(--wp--preset--spacing--40);padding-bottom:var(--wp--preset--spacing--40);padding-left:var(--wp--preset--spacing--40)\">\n<h1 class=\"wp-block-heading has-text-align-center\">Was this post helpful? <\/h1>\n\n\n\n<h3 class=\"wp-block-heading has-text-align-center has-accent-3-color has-text-color has-link-color wp-elements-57a06f07059cd5b947b4a6a2984bc7d9\">Get more help with Tailored Second Opinions for Free! <\/h3>\n\n\n\n<p class=\"has-text-align-center has-contrast-color has-text-color has-link-color wp-elements-672d38dd7dc62ecc2eaa116b5ed44ffa\">Ready to explore better options? <\/p>\n\n\n\n<div class=\"wp-block-buttons is-content-justification-center is-layout-flex wp-container-core-buttons-is-layout-a89b3969 wp-block-buttons-is-layout-flex\">\n<div class=\"wp-block-button\"><a class=\"wp-block-button__link has-base-color has-accent-1-background-color has-text-color has-background has-link-color has-small-font-size has-custom-font-size wp-element-button\" href=\"https:\/\/www.getasecondopinion.ai\/signup\">Claim your free membership <\/a><\/div>\n<\/div>\n\n\n\n<p class=\"has-text-align-center has-contrast-color has-text-color has-link-color wp-elements-59c35e4ddc9021c0e94db1b211deeb40\">and start running reports instantly!&nbsp;<\/p>\n<\/div>\n\n\n\n<h3 class=\"wp-block-heading\"><strong>Reference<\/strong><\/h3>\n\n\n\n<p>FDA \u2014 <a href=\"https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-announces-new-anda-prioritization-pilot-support-us-generic-drug-manufacturing-and-testing\">FDA Announces New ANDA Prioritization Pilot to Support U.S. Generic Drug Manufacturing and Testing<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>The Food and Drug Administration\u2019s new ANDA Prioritization Pilot realigns regulatory incentives to reward onshore bioequivalence testing and U.S. manufacturing of finished dosage forms and active pharmaceutical ingredients (API), and it will strengthen supply\u2011chain resilience, lower inspection costs, and speed patient access to affordable generics. The policy leverages FDA review speed as a targeted market [&hellip;]<\/p>\n","protected":false},"author":3,"featured_media":446,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[42],"tags":[163,164,158,161,162,159,157,165,166,160],"class_list":["post-443","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news","tag-anda-prioritization-pilot","tag-api","tag-bioequivalence","tag-drug-supply-chain","tag-fda","tag-generic-drugs","tag-onshoring","tag-pharma-manufacturing","tag-pharma-policy","tag-us-pharma"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>The ANDA Prioritization Pilot Is a Smart, Strategic Move to Rebuild U.S. Generic Drug Manufacturing Capacity - Get a Second Opinion<\/title>\n<meta name=\"description\" content=\"Explore how the FDA\u2019s new ANDA Prioritization Pilot incentivizes U.S.-based generic drug manufacturing and bioequivalence testing to strengthen supply chain resilience and accelerate affordable access.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.getasecondopinion.ai\/blog\/news\/the-anda-prioritization-pilot-is-a-smart-strategic-move-to-rebuild-u-s-generic-drug-manufacturing-capacity\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"The ANDA Prioritization Pilot Is a Smart, Strategic Move to Rebuild U.S. Generic Drug Manufacturing Capacity - Get a Second Opinion\" \/>\n<meta property=\"og:description\" content=\"Explore how the FDA\u2019s new ANDA Prioritization Pilot incentivizes U.S.-based generic drug manufacturing and bioequivalence testing to strengthen supply chain resilience and accelerate affordable access.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.getasecondopinion.ai\/blog\/news\/the-anda-prioritization-pilot-is-a-smart-strategic-move-to-rebuild-u-s-generic-drug-manufacturing-capacity\/\" \/>\n<meta property=\"og:site_name\" content=\"Get a Second Opinion\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/getasecondopinion\" \/>\n<meta property=\"article:published_time\" content=\"2025-10-06T15:25:30+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-10-06T15:25:31+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.getasecondopinion.ai\/blog\/wp-content\/uploads\/2025\/10\/ANDA-Prioritization-Pilot.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1536\" \/>\n\t<meta property=\"og:image:height\" content=\"1024\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"G2O\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"G2O\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.getasecondopinion.ai\\\/blog\\\/news\\\/the-anda-prioritization-pilot-is-a-smart-strategic-move-to-rebuild-u-s-generic-drug-manufacturing-capacity\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.getasecondopinion.ai\\\/blog\\\/news\\\/the-anda-prioritization-pilot-is-a-smart-strategic-move-to-rebuild-u-s-generic-drug-manufacturing-capacity\\\/\"},\"author\":{\"name\":\"G2O\",\"@id\":\"https:\\\/\\\/www.getasecondopinion.ai\\\/blog\\\/#\\\/schema\\\/person\\\/9fbb863e981c8982fb301d0644843b20\"},\"headline\":\"The ANDA Prioritization Pilot Is a Smart, Strategic Move to Rebuild U.S. Generic Drug Manufacturing Capacity\",\"datePublished\":\"2025-10-06T15:25:30+00:00\",\"dateModified\":\"2025-10-06T15:25:31+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.getasecondopinion.ai\\\/blog\\\/news\\\/the-anda-prioritization-pilot-is-a-smart-strategic-move-to-rebuild-u-s-generic-drug-manufacturing-capacity\\\/\"},\"wordCount\":462,\"publisher\":{\"@id\":\"https:\\\/\\\/www.getasecondopinion.ai\\\/blog\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/www.getasecondopinion.ai\\\/blog\\\/news\\\/the-anda-prioritization-pilot-is-a-smart-strategic-move-to-rebuild-u-s-generic-drug-manufacturing-capacity\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.getasecondopinion.ai\\\/blog\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/ANDA-Prioritization-Pilot.jpg\",\"keywords\":[\"ANDA Prioritization Pilot\",\"API\",\"Bioequivalence\",\"Drug Supply Chain\",\"FDA\",\"Generic Drugs\",\"Onshoring\",\"Pharma Manufacturing\",\"Pharma Policy\",\"US Pharma\"],\"articleSection\":[\"News\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.getasecondopinion.ai\\\/blog\\\/news\\\/the-anda-prioritization-pilot-is-a-smart-strategic-move-to-rebuild-u-s-generic-drug-manufacturing-capacity\\\/\",\"url\":\"https:\\\/\\\/www.getasecondopinion.ai\\\/blog\\\/news\\\/the-anda-prioritization-pilot-is-a-smart-strategic-move-to-rebuild-u-s-generic-drug-manufacturing-capacity\\\/\",\"name\":\"The ANDA Prioritization Pilot Is a Smart, Strategic Move to Rebuild U.S. Generic Drug Manufacturing Capacity - Get a Second Opinion\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.getasecondopinion.ai\\\/blog\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.getasecondopinion.ai\\\/blog\\\/news\\\/the-anda-prioritization-pilot-is-a-smart-strategic-move-to-rebuild-u-s-generic-drug-manufacturing-capacity\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.getasecondopinion.ai\\\/blog\\\/news\\\/the-anda-prioritization-pilot-is-a-smart-strategic-move-to-rebuild-u-s-generic-drug-manufacturing-capacity\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.getasecondopinion.ai\\\/blog\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/ANDA-Prioritization-Pilot.jpg\",\"datePublished\":\"2025-10-06T15:25:30+00:00\",\"dateModified\":\"2025-10-06T15:25:31+00:00\",\"description\":\"Explore how the FDA\u2019s new ANDA Prioritization Pilot incentivizes U.S.-based generic drug manufacturing and bioequivalence testing to strengthen supply chain resilience and accelerate affordable access.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.getasecondopinion.ai\\\/blog\\\/news\\\/the-anda-prioritization-pilot-is-a-smart-strategic-move-to-rebuild-u-s-generic-drug-manufacturing-capacity\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.getasecondopinion.ai\\\/blog\\\/news\\\/the-anda-prioritization-pilot-is-a-smart-strategic-move-to-rebuild-u-s-generic-drug-manufacturing-capacity\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.getasecondopinion.ai\\\/blog\\\/news\\\/the-anda-prioritization-pilot-is-a-smart-strategic-move-to-rebuild-u-s-generic-drug-manufacturing-capacity\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.getasecondopinion.ai\\\/blog\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/ANDA-Prioritization-Pilot.jpg\",\"contentUrl\":\"https:\\\/\\\/www.getasecondopinion.ai\\\/blog\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/ANDA-Prioritization-Pilot.jpg\",\"width\":1536,\"height\":1024,\"caption\":\"Laboratory scene showing a molecular model, a conical flask with orange liquid, a gloved hand using a pipette, and a pill bottle with capsules\u2014overlaid with the title \u201cThe ANDA Prioritization Pilot Is a Smart, Strategic Move to Rebuild U.S. Generic Drug Capacity\u201d on a translucent blue-gray banner for clear readability.\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.getasecondopinion.ai\\\/blog\\\/news\\\/the-anda-prioritization-pilot-is-a-smart-strategic-move-to-rebuild-u-s-generic-drug-manufacturing-capacity\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Insights\",\"item\":\"https:\\\/\\\/www.getasecondopinion.ai\\\/blog\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"News\",\"item\":\"https:\\\/\\\/www.getasecondopinion.ai\\\/blog\\\/category\\\/news\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"The ANDA Prioritization Pilot Is a Smart, Strategic Move to Rebuild U.S. Generic Drug Manufacturing Capacity\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.getasecondopinion.ai\\\/blog\\\/#website\",\"url\":\"https:\\\/\\\/www.getasecondopinion.ai\\\/blog\\\/\",\"name\":\"Get a Second Opinion\",\"description\":\"Insights\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.getasecondopinion.ai\\\/blog\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.getasecondopinion.ai\\\/blog\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.getasecondopinion.ai\\\/blog\\\/#organization\",\"name\":\"Get a Second Opinion\",\"url\":\"https:\\\/\\\/www.getasecondopinion.ai\\\/blog\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.getasecondopinion.ai\\\/blog\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/getasecondopinion.ai\\\/blog\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/G2O-logo-full.png\",\"contentUrl\":\"https:\\\/\\\/getasecondopinion.ai\\\/blog\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/G2O-logo-full.png\",\"width\":1000,\"height\":129,\"caption\":\"Get a Second Opinion\"},\"image\":{\"@id\":\"https:\\\/\\\/www.getasecondopinion.ai\\\/blog\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/getasecondopinion\",\"https:\\\/\\\/www.instagram.com\\\/getasecondopinion\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.getasecondopinion.ai\\\/blog\\\/#\\\/schema\\\/person\\\/9fbb863e981c8982fb301d0644843b20\",\"name\":\"G2O\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/21b03bf2b185bfb0dd4d13c2214225de3355abca7b52e424ee73d37b573644a0?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/21b03bf2b185bfb0dd4d13c2214225de3355abca7b52e424ee73d37b573644a0?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/21b03bf2b185bfb0dd4d13c2214225de3355abca7b52e424ee73d37b573644a0?s=96&d=mm&r=g\",\"caption\":\"G2O\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"The ANDA Prioritization Pilot Is a Smart, Strategic Move to Rebuild U.S. Generic Drug Manufacturing Capacity - Get a Second Opinion","description":"Explore how the FDA\u2019s new ANDA Prioritization Pilot incentivizes U.S.-based generic drug manufacturing and bioequivalence testing to strengthen supply chain resilience and accelerate affordable access.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.getasecondopinion.ai\/blog\/news\/the-anda-prioritization-pilot-is-a-smart-strategic-move-to-rebuild-u-s-generic-drug-manufacturing-capacity\/","og_locale":"en_US","og_type":"article","og_title":"The ANDA Prioritization Pilot Is a Smart, Strategic Move to Rebuild U.S. Generic Drug Manufacturing Capacity - Get a Second Opinion","og_description":"Explore how the FDA\u2019s new ANDA Prioritization Pilot incentivizes U.S.-based generic drug manufacturing and bioequivalence testing to strengthen supply chain resilience and accelerate affordable access.","og_url":"https:\/\/www.getasecondopinion.ai\/blog\/news\/the-anda-prioritization-pilot-is-a-smart-strategic-move-to-rebuild-u-s-generic-drug-manufacturing-capacity\/","og_site_name":"Get a Second Opinion","article_publisher":"https:\/\/www.facebook.com\/getasecondopinion","article_published_time":"2025-10-06T15:25:30+00:00","article_modified_time":"2025-10-06T15:25:31+00:00","og_image":[{"width":1536,"height":1024,"url":"https:\/\/www.getasecondopinion.ai\/blog\/wp-content\/uploads\/2025\/10\/ANDA-Prioritization-Pilot.jpg","type":"image\/jpeg"}],"author":"G2O","twitter_card":"summary_large_image","twitter_misc":{"Written by":"G2O","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.getasecondopinion.ai\/blog\/news\/the-anda-prioritization-pilot-is-a-smart-strategic-move-to-rebuild-u-s-generic-drug-manufacturing-capacity\/#article","isPartOf":{"@id":"https:\/\/www.getasecondopinion.ai\/blog\/news\/the-anda-prioritization-pilot-is-a-smart-strategic-move-to-rebuild-u-s-generic-drug-manufacturing-capacity\/"},"author":{"name":"G2O","@id":"https:\/\/www.getasecondopinion.ai\/blog\/#\/schema\/person\/9fbb863e981c8982fb301d0644843b20"},"headline":"The ANDA Prioritization Pilot Is a Smart, Strategic Move to Rebuild U.S. Generic Drug Manufacturing Capacity","datePublished":"2025-10-06T15:25:30+00:00","dateModified":"2025-10-06T15:25:31+00:00","mainEntityOfPage":{"@id":"https:\/\/www.getasecondopinion.ai\/blog\/news\/the-anda-prioritization-pilot-is-a-smart-strategic-move-to-rebuild-u-s-generic-drug-manufacturing-capacity\/"},"wordCount":462,"publisher":{"@id":"https:\/\/www.getasecondopinion.ai\/blog\/#organization"},"image":{"@id":"https:\/\/www.getasecondopinion.ai\/blog\/news\/the-anda-prioritization-pilot-is-a-smart-strategic-move-to-rebuild-u-s-generic-drug-manufacturing-capacity\/#primaryimage"},"thumbnailUrl":"https:\/\/www.getasecondopinion.ai\/blog\/wp-content\/uploads\/2025\/10\/ANDA-Prioritization-Pilot.jpg","keywords":["ANDA Prioritization Pilot","API","Bioequivalence","Drug Supply Chain","FDA","Generic Drugs","Onshoring","Pharma Manufacturing","Pharma Policy","US Pharma"],"articleSection":["News"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.getasecondopinion.ai\/blog\/news\/the-anda-prioritization-pilot-is-a-smart-strategic-move-to-rebuild-u-s-generic-drug-manufacturing-capacity\/","url":"https:\/\/www.getasecondopinion.ai\/blog\/news\/the-anda-prioritization-pilot-is-a-smart-strategic-move-to-rebuild-u-s-generic-drug-manufacturing-capacity\/","name":"The ANDA Prioritization Pilot Is a Smart, Strategic Move to Rebuild U.S. Generic Drug Manufacturing Capacity - Get a Second Opinion","isPartOf":{"@id":"https:\/\/www.getasecondopinion.ai\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.getasecondopinion.ai\/blog\/news\/the-anda-prioritization-pilot-is-a-smart-strategic-move-to-rebuild-u-s-generic-drug-manufacturing-capacity\/#primaryimage"},"image":{"@id":"https:\/\/www.getasecondopinion.ai\/blog\/news\/the-anda-prioritization-pilot-is-a-smart-strategic-move-to-rebuild-u-s-generic-drug-manufacturing-capacity\/#primaryimage"},"thumbnailUrl":"https:\/\/www.getasecondopinion.ai\/blog\/wp-content\/uploads\/2025\/10\/ANDA-Prioritization-Pilot.jpg","datePublished":"2025-10-06T15:25:30+00:00","dateModified":"2025-10-06T15:25:31+00:00","description":"Explore how the FDA\u2019s new ANDA Prioritization Pilot incentivizes U.S.-based generic drug manufacturing and bioequivalence testing to strengthen supply chain resilience and accelerate affordable access.","breadcrumb":{"@id":"https:\/\/www.getasecondopinion.ai\/blog\/news\/the-anda-prioritization-pilot-is-a-smart-strategic-move-to-rebuild-u-s-generic-drug-manufacturing-capacity\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.getasecondopinion.ai\/blog\/news\/the-anda-prioritization-pilot-is-a-smart-strategic-move-to-rebuild-u-s-generic-drug-manufacturing-capacity\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.getasecondopinion.ai\/blog\/news\/the-anda-prioritization-pilot-is-a-smart-strategic-move-to-rebuild-u-s-generic-drug-manufacturing-capacity\/#primaryimage","url":"https:\/\/www.getasecondopinion.ai\/blog\/wp-content\/uploads\/2025\/10\/ANDA-Prioritization-Pilot.jpg","contentUrl":"https:\/\/www.getasecondopinion.ai\/blog\/wp-content\/uploads\/2025\/10\/ANDA-Prioritization-Pilot.jpg","width":1536,"height":1024,"caption":"Laboratory scene showing a molecular model, a conical flask with orange liquid, a gloved hand using a pipette, and a pill bottle with capsules\u2014overlaid with the title \u201cThe ANDA Prioritization Pilot Is a Smart, Strategic Move to Rebuild U.S. Generic Drug Capacity\u201d on a translucent blue-gray banner for clear readability."},{"@type":"BreadcrumbList","@id":"https:\/\/www.getasecondopinion.ai\/blog\/news\/the-anda-prioritization-pilot-is-a-smart-strategic-move-to-rebuild-u-s-generic-drug-manufacturing-capacity\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Insights","item":"https:\/\/www.getasecondopinion.ai\/blog\/"},{"@type":"ListItem","position":2,"name":"News","item":"https:\/\/www.getasecondopinion.ai\/blog\/category\/news\/"},{"@type":"ListItem","position":3,"name":"The ANDA Prioritization Pilot Is a Smart, Strategic Move to Rebuild U.S. Generic Drug Manufacturing Capacity"}]},{"@type":"WebSite","@id":"https:\/\/www.getasecondopinion.ai\/blog\/#website","url":"https:\/\/www.getasecondopinion.ai\/blog\/","name":"Get a Second Opinion","description":"Insights","publisher":{"@id":"https:\/\/www.getasecondopinion.ai\/blog\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.getasecondopinion.ai\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.getasecondopinion.ai\/blog\/#organization","name":"Get a Second Opinion","url":"https:\/\/www.getasecondopinion.ai\/blog\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.getasecondopinion.ai\/blog\/#\/schema\/logo\/image\/","url":"https:\/\/getasecondopinion.ai\/blog\/wp-content\/uploads\/2025\/09\/G2O-logo-full.png","contentUrl":"https:\/\/getasecondopinion.ai\/blog\/wp-content\/uploads\/2025\/09\/G2O-logo-full.png","width":1000,"height":129,"caption":"Get a Second Opinion"},"image":{"@id":"https:\/\/www.getasecondopinion.ai\/blog\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/getasecondopinion","https:\/\/www.instagram.com\/getasecondopinion"]},{"@type":"Person","@id":"https:\/\/www.getasecondopinion.ai\/blog\/#\/schema\/person\/9fbb863e981c8982fb301d0644843b20","name":"G2O","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/21b03bf2b185bfb0dd4d13c2214225de3355abca7b52e424ee73d37b573644a0?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/21b03bf2b185bfb0dd4d13c2214225de3355abca7b52e424ee73d37b573644a0?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/21b03bf2b185bfb0dd4d13c2214225de3355abca7b52e424ee73d37b573644a0?s=96&d=mm&r=g","caption":"G2O"}}]}},"_links":{"self":[{"href":"https:\/\/www.getasecondopinion.ai\/blog\/wp-json\/wp\/v2\/posts\/443","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.getasecondopinion.ai\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.getasecondopinion.ai\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.getasecondopinion.ai\/blog\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/www.getasecondopinion.ai\/blog\/wp-json\/wp\/v2\/comments?post=443"}],"version-history":[{"count":1,"href":"https:\/\/www.getasecondopinion.ai\/blog\/wp-json\/wp\/v2\/posts\/443\/revisions"}],"predecessor-version":[{"id":444,"href":"https:\/\/www.getasecondopinion.ai\/blog\/wp-json\/wp\/v2\/posts\/443\/revisions\/444"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.getasecondopinion.ai\/blog\/wp-json\/wp\/v2\/media\/446"}],"wp:attachment":[{"href":"https:\/\/www.getasecondopinion.ai\/blog\/wp-json\/wp\/v2\/media?parent=443"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.getasecondopinion.ai\/blog\/wp-json\/wp\/v2\/categories?post=443"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.getasecondopinion.ai\/blog\/wp-json\/wp\/v2\/tags?post=443"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}